Our most advanced programs address disease areas of significant clinical interest.
Rare genetic disorders
|Disease Area||Clinical POC*||Platform Discovery||Early Clinical||Late Clinical|
|Rare genetic disorders|
|* Clinical POC defined as clinical efficacy signals with a structurally-related compound to Kaleido Leads|
Two key aspects of our strategy enable Kaleido to bring products to the clinic on a shorter timeline compared with traditional drug development efforts.
Our compound library includes sources of chemistry predominantly found in foods, significantly reducing safety concerns.
Our R&D engine makes it possible to study the human microbiome directly in a laboratory setting, which streamlines and accelerates the assessment of patient responses and inter-individual variability.